Work

IL-17A blockade alleviates immune checkpoint inhibitor-associated psoriasiform rash: preclinical and clinical responses

Year: 2025

Type: article

Abstract: Psoriasiform rash is a notable immune-related cutaneous adverse event (ircAE) accounting for approximately 5% of all ircAEs[1][1],[2][2]. Patients with cancer and pre-existing psoriasis face elevated risk of disease recurrence or exacerbation after receiving immune checkpoint inhibitors (ICIs). A

Source: Cancer Biology and Medicine

DOI: 10.20892/j.issn.2095-3941.2025.0344